Amarin Settlement With Apotex An 'Incremental Positive,' Says Stifel

Stifel analyst Derek Archila reiterates his Hold rating on Amarin shares after the company settled with Apotex regarding its ANDA application for generic Vascepa.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.